Tirzepatide is the first drug in a new family of medicines that target two hormones - glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) - that are involved in maintaining healthy blood sugar levels, breaking down fat, and reducing appetite by sending signals from the gut to the brain when people are full
Sankhala K, Takimoto C, Mita A, Xiong H, Rodon JA, Adinin R, Burns K, Toko T, Arakawa K, Kopetz S
Initial loading phases involve 6-12 total injections over 4-8 weeks, followed by maintenance every 2-4 weeks indefinitely
However, not everyone is a good candidate for GLP-1 injections
When conducting Fourier transform infrared spectroscopy analysis, we took NPs, GLP-1RAs@NPs, and GLP-1RAs@NPs-WYRGRL solutions, centrifuged them to obtain the precipitates, and then freeze-dried the precipitates